Endometrial Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Endometrial Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 6 companies, in the next 180 days.
August 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CORT | Corcept Therapeutics | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Progression-Free Survival (PFS) | Phase 2 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-16 |
| KPTI | Karyopharm Therapeutics Inc | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931Investigator assessed Progression Free Survival (PFS) per RECIST v1.1 | Phase 3 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-05-29 |
| RADX | Radiopharm Theranostics, Ltd | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-17 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| IDYA | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-13 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| NXTC | NextCure, Inc. | A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-12-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Endometrial Cancer
most recently updated first109 studies match. Showing the first 100 of 109 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| WHWK | Whitehawk Therapeutics, Inc. | $271M | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.NCT07470853Determine Maximum Tolerated Dose (MTD) | Phase 1 | Recruiting | Drug: HWK-016, MUCIN-16-targeted ADC, Bevacizumab | PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer | 265 | 2026-03-15 | Feb 2028 | ≤ 558 d | 2026-08-18 |
| PFE | Pfizer | $155.3B | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerNCT07578649Progression-Free Survival (PFS) using RECIST v1.1 as assessed by Blinded Independent Central Review (BICR) | Phase 3 | Not yet recruiting | Biological: PF-08634404, Pembrolizumab · Drug: Standard of Care Chemotherapy | Endometrial Neoplasms, Endometrial Cancer | 600 | 2026-10-09 | 2029-06-01 | in 1,016 d | 2026-08-17 |
| AZN | AstraZeneca | — | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR) | Phase 2 | Recruiting | Drug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | 454 | 2022-09-06 | 2027-10-01 | in 407 d | 2026-08-13 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2022-10-06 | 2025-04-30actual | — | 2026-08-13 |
| AZN | AstraZeneca | — | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) | Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | 460 | 2021-10-18 | 2027-09-29 | in 405 d | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| AZN | AstraZeneca | — | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerNCT06989112Progression-free survival (PFS), as assessed by BICR | Phase 3 | Recruiting | Drug: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel | Endometrial Cancer | 600 | 2025-03-27 | 2029-01-19 | in 883 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| AZN | AstraZeneca | — | An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian FederationNCT07041606observationalThe rate of POLEm positive status | — | Recruiting | — | Endometrial Cancer | 500 | 2025-06-24 | 2027-06-30 | in 314 d | 2026-08-10 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.NCT07755436Treatment-Emergent Adverse Event (TEAE) | Phase 1 | Recruiting | Drug: ARR-002 | Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic Endometrial Cancer | 180 | 2026-07-23 | Aug 2027 | ≤ 376 d | 2026-08-10 |
| AZN | AstraZeneca | — | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerNCT04269200results2025-12-23Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments | Phase 3 | Active, not recruiting | Drug: olaparib, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel · Biological: durvalumab | Endometrial Neoplasms | 805 | 2020-05-05 | 2024-07-08actual | — | 2026-08-07 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496 | Phase 1 | Recruiting | Drug: LY4257496, Standard of Care Anticancer Therapies · Diagnostic test: LY4257529 | Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms | 421 | 2025-08-06 | Apr 2030 | ≤ 1,349 d | 2026-08-06 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | 2025-11-07 | Dec 2027 | ≤ 498 d | 2026-08-06 |
| WHWK | Whitehawk Therapeutics, Inc. | $271M | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsNCT07444814Determine Maximum Tolerated Dose (MTD) | Phase 1 | Recruiting | Drug: HWK-007 | Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC | 226 | 2025-12-19 | Oct 2028 | ≤ 803 d | 2026-08-05 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 Study of the Safety and Tolerability of CTX-10726NCT07419841Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses | Phase 1 | Recruiting | Drug: CTX-10726 | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | 2026-05-28 | 2028-04-01 | in 590 d | 2026-07-31 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)NCT06486441Progression-Free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) | Phase 3 | Active, not recruiting | Drug: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel | Endometrial Cancer | 640 | 2024-08-28 | Jun 2029 | ≤ 1,045 d | 2026-07-29 |
| AZN | AstraZeneca | — | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)NCT07044336Progression Free Survival (PFS) for Arm A vs Arm B | Phase 3 | Recruiting | Drug: Puxitatug Samrotecan, Doxorubicin, Paclitaxel | Endometrial Cancer, Malignant Solid Tumour | 800 | 2025-08-01 | 2027-10-15 | in 421 d | 2026-07-29 |
| AZN | AstraZeneca | — | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumors | Phase 1 | Recruiting | Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D | Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D | 108 | 2024-03-22 | 2027-08-30 | in 375 d | 2026-07-28 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial CancerNCT07022483Disease-Free Survival as Assessed by Blinded Independent Central Review or by Histopathologic Confirmation of Disease Recurrence per Local Assessment | Phase 3 | Recruiting | Drug: Trastuzumab Deruxtecan, Chemotherapy | Endometrial Cancer | 710 | 2025-09-30 | 2032-03-23 | in 2,042 d | 2026-07-28 |
| AZN | AstraZeneca | — | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsNCT05797168Number of participants with adverse events/serious adverse events | Phase 1/2 | Recruiting | Drug: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab | Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma | 602 | 2023-06-05 | 2028-08-04 | in 715 d | 2026-07-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersNCT03564340Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapy | Phase 1/2 | Recruiting | Drug: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer | 890 | 2018-05-21 | 2027-05-10 | in 263 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2022-10-25 | 2028-01-05 | in 503 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2NCT06003231Confirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment | Phase 2 | Active, not recruiting | Drug: disitamab vedotin | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms | 120 | 2023-11-14 | 2026-03-27actual | — | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| BNTX | BioNTech SE | — | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerNCT06340568Cohort 1: PFS assessed by blinded independent central review (BICR) in participants with HER2 IHC 1+/2+ recurrent endometrial cancer | Phase 3 | Recruiting | Drug: BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel | Endometrial Cancer | 480 | 2025-06-10 | Mar 2028 | ≤ 589 d | 2026-07-21 |
| RADX | Radiopharm Theranostics, Ltd | — | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Drug: RAD301 ([68Ga]-RAD301) | Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer | 9 | 2023-11-09 | Aug 2026 | ≤ 11 d | 2026-07-17 |
| CORT | Corcept Therapeutics | $12.8B | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Progression-Free Survival (PFS) | Phase 2 | Recruiting | Drug: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer | 270 | 2025-04-11 | Aug 2026 | ≤ 11 d | 2026-07-16 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Drug: IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | 216 | 2023-04-18 | Oct 2026 | ≤ 72 d | 2026-07-13 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| COGT | Cogent Biosciences, Inc. | $6.4B | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsNCT07383506Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Phase 1a] | Phase 1 | Recruiting | Drug: CGT6297 | PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer | 90 | Jun 2026 | Jul 2029 | ≤ 1,076 d | 2026-07-01 |
| AZN | AstraZeneca | — | NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)NCT06890273observationalReal-world Time To Next Treatment (rwTTNT) | — | Recruiting | — | Endometrial Cancer | 150 | 2025-05-20 | 2029-03-31 | in 954 d | 2026-06-24 |
| AZN | AstraZeneca | — | Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing SurveillanceNCT06995833observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs) | — | Recruiting | — | Endometrial Cancer | 50 | 2025-09-19 | 2029-06-29 | in 1,044 d | 2026-06-24 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4175408 in Participants With Advanced CancerNCT07046923Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408 | Phase 1 | Recruiting | Drug: LY4175408, Pembrolizumab, Carboplatin, Cisplatin | Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer | 240 | 2025-07-28 | Jul 2030 | ≤ 1,441 d | 2026-06-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerNCT04188548Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities | Phase 1 | Active, not recruiting | Drug: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab | Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer | 379 | 2019-12-10 | 2020-06-29actual | — | 2026-06-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4170156 in Participants With Selected Advanced Solid TumorsNCT06400472Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156 | Phase 1 | Recruiting | Drug: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumab | Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms | 495 | 2024-05-20 | Feb 2027 | ≤ 192 d | 2026-06-18 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalation | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2026-02-24 | 2027-07-30 | in 344 d | 2026-06-18 |
| NTRA | Natera, Inc. | $44.9B | Signatera Assessment in Early-Stage Endometrial CancerNCT07339384Recurrence Free Survival (RFS) | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | Endometrial Cancer | 1,010 | Oct 2026 | Oct 2034 | ≤ 2,994 d | 2026-06-17 |
| CNTX | Context Therapeutics Inc. | $49M | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsNCT06515613Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: CTIM-76 | Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer | 156 | 2024-07-10 | 2028-05-31 | in 650 d | 2026-06-16 |
| INCY | Incyte Corporation | $24.7B | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.NCT04463771Group A - Objective Response Rate | Phase 2 | Completed | Drug: retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390 | Endometrial Cancer | 206 | 2021-01-26 | 2026-05-29actual | — | 2026-06-11 |
| XNCR | Xencor, Inc. | $1.9B | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsNCT06276491Incidence of adverse events | Phase 1 | Recruiting | Biological: XmAb541 | Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor | 282 | 2024-04-04 | Dec 2027 | ≤ 498 d | 2026-06-11 |
| MGNX | MacroGenics | $261M | A Study of Lorigerlimab in Participants With Advanced Solid TumorsNCT06730347Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator | Phase 2 | Recruiting | Biological: Lorigerlimab | Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer | 80 | 2025-05-01 | Jul 2027 | ≤ 345 d | 2026-06-02 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy | Phase 1/2 | Active, not recruiting | Drug: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms | 540 | 2021-07-19 | Apr 2027 | ≤ 253 d | 2026-05-29 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931Investigator assessed Progression Free Survival (PFS) per RECIST v1.1 | Phase 3 | Active, not recruiting | Drug: Selinexor, Matching Placebo for selinexor | Endometrial Cancer | 257 | 2023-04-18 | Aug 2026 | ≤ 11 d | 2026-05-29 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422Progression Free Survival (PFS) | Phase 3 | Completed | Drug: Selinexor, Matching placebo for selinexor | Endometrial Cancer | 263 | 2018-01-05 | 2022-01-22actual | — | 2026-04-13 |
| AZN | AstraZeneca | — | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsNCT06973161observationalOverall Survival | — | Completed | — | Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors | 140 | 2025-06-10 | 2026-03-17actual | — | 2026-04-08 |
| EIKN | Eikon Therapeutics | $567M | EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsNCT07262619Dose-Limiting Toxicity (DLT) - Part 1 | Phase 1/2 | Recruiting | Drug: EIK1005, pembrolizumab (KEYTRUDA® ) | Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors | 160 | 2026-01-20 | Mar 2029 | ≤ 954 d | 2026-04-08 |
| FATE | Fate Therapeutics | $307M | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsNCT07216105Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: FT836, Paclitaxel, Cetuximab, Trastuzumab | Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma | 113 | 2025-11-04 | Jan 2028 | ≤ 529 d | 2026-04-07 |
| AGEN | Agenus Inc. | $339M | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerNCT03860272Incidence Of Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Drug: Botensilimab, Balstilimab | Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer | 499 | 2019-03-20 | 2025-01-13actual | — | 2026-03-30 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) | Phase 1/2 | Recruiting | Drug: 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | 61 | 2026-02-23 | Dec 2027 | ≤ 498 d | 2026-03-27 |
| 4523.T | Eisai Inc. | $8.7B | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorNCT04008797Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs) | Phase 1/2 | Active, not recruiting | Drug: E7386, Lenvatinib, Doxorubicin, Paclitaxel | Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms | 301 | 2019-07-11 | 2027-03-31 | in 223 d | 2026-03-24 |
| 4523.T | Eisai Inc. | $8.7B | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])NCT03517449results2021-11-17Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants | Phase 3 | Completed | Drug: Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin | Endometrial Neoplasms | 827 | 2018-06-11 | 2022-03-01actual | — | 2026-03-19 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Karyopharm Expanded Access Program for SelinexorNCT07215832expanded access | — | Available | Drug: selinexor | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma, Endometrial Cancer, Myelofibrosis, Other | — | — | — | — | 2026-03-02 |
| ABBV | AbbVie | $457.5B | First in Human Study of IMGN151 in Recurrent Gynaecological CancersNCT05527184Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: IMGN151 | Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer | 256 | 2023-01-11 | Feb 2027 | ≤ 192 d | 2026-02-20 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962Time Activity Curves (TACs) | Early Phase 1 | Recruiting | Drug: 177Lu-RAD204 | PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer, Cutaneous Melanoma, HNSCC, Endometrial Cancer, Mmr Deficiency, MSI-High | 30 | 2024-06-03 | Dec 2027 | ≤ 498 d | 2026-02-19 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Drug: Felmetatug Vedotin, Pembrolizumab | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma | 250 | 2022-01-12 | 2025-05-14actual | — | 2026-01-09 |
| NXTC | NextCure, Inc. | $30M | A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74 | Phase 1 | Recruiting | Drug: LNCB74 | Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors | 145 | 2025-01-07 | Dec 2026 | ≤ 133 d | 2025-12-16 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabNCT04590326Incidence of Dose Limiting Toxicities (DLT) | Phase 1/2 | Recruiting | Drug: REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 612 | 2020-12-08 | 2027-03-25 | in 217 d | 2025-11-21 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in TaiwanNCT06925113observationalTo understand the prevalence rate of HER2 IHC 3+ in recurrent advanced endometrial cancer, ovarian cancer, and cervical cancer in Taiwan | — | Completed | — | Cervical Cancers, Endometrial Cancer, Ovarian Cancer | 509 | 2025-01-31 | 2025-08-31actual | — | 2025-11-17 |
| TCRT | Alaunos Therapeutics | $5M | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsNCT05194735results2025-11-10Number of Participants With Treatment-Emergent Adverse Events | Phase 1/2 | Terminatedsponsor's stated reason: Funding | Biological: Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2) | Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer | 8 | 2022-04-04 | 2023-08-14actual | — | 2025-11-10 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.NCT06481592Objective Response Rate | Phase 2 | Recruiting | Biological: Lifileucel | Endometrial Cancer | 60 | 2024-10-29 | May 2028 | ≤ 650 d | 2025-10-30 |
| TEM | Tempus AI | $8.6B | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437results2025-10-29Overall Response Rate (ORR) - Independent Central Review (ICR) | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges | Drug: Niraparib | Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer | 22 | 2022-03-15 | 2024-08-06actual | — | 2025-10-29 |
| TPST | Tempest Therapeutics | $16M | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsNCT04344795Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab | Phase 1 | Completed | Drug: TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab | Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation | 89 | 2020-05-06 | 2024-09-25actual | — | 2025-09-12 |
| GH | Guardant Health, Inc. | $21.5B | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444observationalDistant Recurrence Free Interval (D-RFi) | — | Recruiting | Diagnostic test: Guardant Reveal | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 2,020 | 2021-09-07 | Aug 2029 | ≤ 1,107 d | 2025-08-22 |
| STRO | Sutro Biopharma, Inc. | $365M | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersNCT03748186Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002) | Phase 1 | Completed | Drug: STRO-002 | Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 136 | 2019-02-01 | 2024-06-04actual | — | 2025-08-20 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| INCY | Incyte Corporation | $24.7B | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid TumorsNCT03314935results2023-12-07Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1/2 | Completed | Drug: INCB001158, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, Cisplatin, Paclitaxel | Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors | 149 | 2017-11-21 | 2022-11-28actual | — | 2025-08-12 |
| TCRT | Alaunos Therapeutics | $5M | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid TumorsNCT05124743observationalNumber of Participants Positive for Human Leukocyte Antigen (HLA)-A*02 | — | Terminatedsponsor's stated reason: TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business decisions. | — | Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma, Non-small Cell Lung Cancer, Pancreas Cancer | 19 | 2021-09-24 | 2023-08-14actual | — | 2025-07-30 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Study to Investigate LYL797 in Adults With Solid TumorsNCT05274451Evaluate incidence of dose-limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Pipeline Reprioritization | Biological: LYL797 | Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer | 57 | 2022-03-29 | 2024-11-27actual | — | 2025-07-01 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Biomarker Screening Protocol for Participants With Solid TumorsNCT05891197observationalTo identify participants whose tumors express biomarkers, such as ROR1, that may inform eligibility for active and future Lyell clinical trials | — | Terminatedsponsor's stated reason: Pipeline Reprioritization | — | Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer | 10 | 2023-05-19 | 2025-02-05actual | — | 2025-07-01 |
| AZN | AstraZeneca | — | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesNCT01226316Parts A,B,C,D,E & F : Safety and tolerability of AZD5363 in terms of adverse events and serious adverse events | Phase 1 | Completed | Drug: AZD5363, AZD5363, AZD5363, AZD5363 | Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive | 285 | 2010-12-01 | 2019-04-26actual | — | 2025-06-29 |
| PFE | Pfizer | $155.3B | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding | Phase 1 | Terminatedsponsor's stated reason: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-06940434, PF-06801591 | Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer | 85 | 2019-11-13 | 2024-12-10actual | — | 2025-05-28 |
| PFE | Pfizer | $155.3B | A Study of PF-07260437 in Advanced or Metastatic Solid TumorsNCT05067972results2025-05-06Number of Participants With Dose-Limiting Toxicities (DLTs) in Dose Escalation - Part 1 | Phase 1 | Terminatedsponsor's stated reason: Pfizer has made an internal business decision to not continue further development of PF-07260437. This decision was not due to major safety concerns or requests from any regulatory authorities. | Drug: PF-07260437 · Diagnostic test: B7-H4 IHC | Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms | 30 | 2021-10-07 | 2023-10-17actual | — | 2025-05-06 |
| EXEL | Exelixis | $13.2B | Study of XB002 in Subjects With Solid Tumors (JEWEL-101)NCT04925284Dose-Escalation Stage: MTD/recommended dose for XB002 | Phase 1 | Completed | Drug: XB002, Nivolumab, Bevacizumab | Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors | 269 | 2021-06-07 | 2025-03-10actual | — | 2025-04-04 |
| BPTH | Bio-Path Holdings, Inc. | $2M | BP1001-A in Patients With Advanced or Recurrent Solid TumorsNCT04196257Identify Dose Limiting Toxicity (DLT) of BP1001-A | Phase 1 | Recruiting | Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel | Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer, Peritoneal Cancer, Solid Tumor | 50 | 2022-08-19 | Jul 2027 | ≤ 345 d | 2025-03-07 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesNCT05032040PSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohorts | Phase 2 | Active, not recruiting | Biological: vudalimab | Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 170 | 2022-07-21 | 2025-10-15 | — | 2025-02-07 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2019-05-01 | 2024-02-15actual | — | 2024-07-05 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsNCT05538572Dose limiting toxicity (DLT) of PRT3645 | Phase 1 | Completed | Drug: PRT3645 | Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer | 22 | 2022-12-27 | 2024-06-26actual | — | 2024-07-01 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesNCT03629756Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: Etrumadenant, Zimberelimab | Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer | 48 | 2018-07-24 | 2021-08-18actual | — | 2024-05-24 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of DeTIL-0255 in Adults With Advanced MalignanciesNCT05107739Incidence of treatment emergent adverse events | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: Drug Product De-TIL-0255 | Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer | 5 | 2021-12-22 | 2023-05-09actual | — | 2024-05-03 |
| NXTC | NextCure, Inc. | $30M | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsNCT03665285results2024-03-08Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Completed | Drug: NC318 | Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma | 109 | 2018-10-01 | 2023-04-11actual | — | 2024-03-08 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersNCT03454451Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. | Phase 1 | Completed | Drug: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab | Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma | 117 | 2018-04-25 | 2022-12-28actual | — | 2023-12-21 |
| 4523.T | Eisai Inc. | $8.7B | Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease ProgressionNCT01111461results2016-04-18Objective Response Rate (ORR) | Phase 2 | Completed | Drug: Lenvatinib | Endometrial Cancer | 133 | Mar 2010 | May 2012actual | — | 2023-06-22 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2019-05-29 | 2023-02-16actual | — | 2023-03-30 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic MalignanciesNCT02025985results2021-02-02Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Phase 2 | Completed | Drug: Selinexor | Ovarian Carcinoma, Endometrial Carcinoma, Cervical Carcinoma | 116 | 2014-04-09 | 2017-01-24actual | — | 2023-01-26 |
| INCY | Incyte Corporation | $24.7B | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)NCT02393248results2023-01-06Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1/2 | Terminated | Drug: Pemigatinib, Gemcitabine, Pembrolizumab, Docetaxel, Trastuzumab, Retifanlimab, Cisplatin | Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN | 201 | 2015-02-27 | 2021-12-17actual | — | 2023-01-06 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488Determine the safety and tolerability profile of XmAb20717 | Phase 1 | Completed | Biological: XmAb20717 | Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma | 150 | 2018-07-10 | 2022-06-01actual | — | 2022-12-01 |
| XBIO | Xenetic Biosciences, Inc. | $8M | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial CancerNCT03077698results2022-06-07Overall Disease Control (ODC) as Determined by Radiographic Imaging Measurements | Phase 2 | Terminatedsponsor's stated reason: The study was discontinued due to a change in development strategy and not due safety concern. | Drug: Sodium Cridanimod, progestin therapy | Endometrial Cancer | 25 | 2017-06-14 | 2020-07-17actual | — | 2022-06-07 |
| INCY | Incyte Corporation | $24.7B | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsNCT02646748Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events | Phase 1 | Completed | Drug: Pembrolizumab, itacitinib, INCB050465 | Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer, Lung Cancer, MMR-deficient Tumors, Breast Cancer, Pancreatic Cancer, Renal Cell Carcinoma (RCC), Solid Tumors, UC (Urothelial Cancer) | 159 | 2016-01-25 | 2019-11-07actual | — | 2022-03-31 |
| INCY | Incyte Corporation | $24.7B | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersNCT02178722results2019-12-19Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events | Phase 1/2 | Completed | Drug: MK-3475, INCB024360 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC) | 444 | 2014-07-17 | 2018-11-26actual | — | 2022-02-14 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerNCT01631552results2021-04-06Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events | Phase 1/2 | Completed | Drug: Sacituzumab Govitecan-hziy (SG) | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | 515 | 2012-12-17 | 2019-03-01actual | — | 2021-08-12 |
| IPN.PA | Ipsen | $15.5B | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial CancerNCT00910091results2015-09-30Percentage of Women With Advanced or Recurrent Endometrial Cancer Who Have Neither Progressed Nor Died | Phase 2 | Completed | Drug: BN83495, Megestrol Acetate (MA) | Endometrial Cancer | 73 | Aug 2009 | Jan 2012actual | — | 2019-01-30 |
| IPN.PA | Ipsen | $15.5B | Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapyNCT01251354results2015-09-02Determination of Clinical Benefit (CB), Defined as Sum of Patients Who Present Complete Response (CR), Partial Response (PR) or Stable Disease (SD) ≥12 Weeks (CB=CR+PR+SD≥12 Weeks) Using Response Evaluation Criteria in Solid Tumors (RECIST Version1.1) | Phase 2 | Terminatedsponsor's stated reason: The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached. | Drug: BN83495 | Endometrial Cancer | 6 | Nov 2010 | Jun 2011actual | — | 2019-01-14 |
| PFE | Pfizer | $155.3B | A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial CancerNCT01420081results2015-05-19Clinical Benefit Response for PF-04691502 | Phase 2 | Terminatedsponsor's stated reason: See termination reason in detailed description. | Drug: PF-05212384, PF-05212384, PF-05212384 | Endometrial Neoplasms | 67 | 2012-01-19 | 2014-04-30actual | — | 2019-01-08 |
| 2802.T | Ajinomoto Co., Inc. | $35.2B | Biomarkers for Gynecologic CancerNCT02178462observationalPerformance characteristics of AminoIndexTM biomarker to discriminate gynecologic cancer from benign disease or healthy subjects | — | Unknown status | — | Ovarian Cancer, Endometrial Cancer, Benign Gynecological Disease | 153 | Jun 2014 | Mar 2018 | — | 2018-01-31 |
| ALMKT.PA | Mauna Kea Technologies | $5,661 | Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.NCT02221076The number of participants with adverse events, their type and severity. | Not applicable | Completed | Device: Confocal Laser Endomicroscopy (CLE) | Cervix Cancer, Endometrium Cancer, Ovarian Cancer, Carcinoma in Situ of Fallopian Tube | 16 | Jul 2014 | 2016-04-18actual | — | 2017-08-29 |
| AMGN | Amgen | $229.9B | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaNCT01444456results2014-08-15observationalPercentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL | — | Completed | — | Anemia, Breast Cancer, Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Solid Tumors, Bladder Cancer, Endometrial Cancer, Renal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer | 1,262 | Oct 2011 | Aug 2013actual | — | 2017-03-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Endometrial Cancer is matched — 4 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Endometrial Cancer
- Endometrial Neoplasms
- Endometrial Carcinoma
- Endometrium Cancer
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Endometrial Cancer” (a text search, wider than this page)